市場調查報告書
商品編碼
966723

復發型多發性硬化症(RRMS)市場:洞察,流行病學及2030年前的預測

Relapsing-Remitting Multiple Sclerosis (RRMS) - Market Insight, Epidemiology and Market Forecast - 2030

出版日期: 按訂單生產 | 出版商: DelveInsight Business Research LLP | 英文 200 Pages | 商品交期: 2-10個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供世界主要7個國家(美國,歐洲5個國家(德國,西班牙,義大利,法國,及英國),日本)的復發型多發性硬化症(RRMS)市場的相關調查,提供流行病學,市場規模和預測,成長要素及課題,治療方法·各國市場分析,競爭情形,主要企業的產品等資訊。

目錄

第1章 主要洞察

第2章 摘要整理

第3章 競爭資訊分析

第4章 市場概要

  • 2017年:整體市場佔有率
  • 2030年:整體市場佔有率

第5章 疾病的背景和概要

  • 簡介
  • 徵兆與症狀
  • 病理學
  • 危險因素
  • 診斷

第6章 患者的治療過程

第7章 流行病學及患者人口

  • 流行病學的主要調查結果
  • 前提條件與理論的根據:主要7個國家
  • 流行病學方案:主要7個國家
  • 美國流行病學
  • 各國流行病學歐洲5個國家
    • 德國流行病學
    • 法國流行病學
    • 義大利流行病學
    • 西班牙流行病學
    • 英國流行病學
  • 日本流行病學

第8章 治療流程,目前治療,及醫務

  • 治療和管理
  • 治療流程

第9章 未滿足需求

第10章 主要評估項目

第11章 市售產品

第12章 新治療方法

第13章 主要7個國家的市場分析

  • 主要調查結果
  • 市場規模
  • 各治療法的市場規模

第14章 屬性分析

第15章 主要7個國家:市場預測

  • 美國:市場規模
    • 整體市場規模
    • 各治療法市場規模
  • 歐洲五個國家:市場規模和前景
  • 德國的市場規模
  • 法國的市場規模
  • 義大利的市場規模
  • 西班牙的市場規模
  • 英國的市場規模
  • 日本的市場規模

第16章 就醫與給付

第17章 KOL的見解

第18章 市場成長要素

第19章 市場障礙

第20章 附錄

  • 參考文獻
  • 報告的調查手法

第21章 DelveInsight的服務內容

第22章 免責聲明

第23章 關於DelveInsight

目錄
Product Code: DIMI1126

DelveInsight's "Relapsing-Remitting Multiple Sclerosis (RRMS) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Relapsing-Remitting Multiple Sclerosis (RRMS) , historical and forecasted epidemiology as well as the Relapsing-Remitting Multiple Sclerosis (RRMS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Relapsing-Remitting Multiple Sclerosis (RRMS) market report provides current treatment practices, emerging drugs, Relapsing-Remitting Multiple Sclerosis (RRMS) market share of the individual therapies, current and forecasted Relapsing-Remitting Multiple Sclerosis (RRMS) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Relapsing-Remitting Multiple Sclerosis (RRMS) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Relapsing-Remitting Multiple Sclerosis (RRMS) Disease Understanding and Treatment Algorithm

The DelveInsight Relapsing-Remitting Multiple Sclerosis (RRMS) market report gives a thorough understanding of the Relapsing-Remitting Multiple Sclerosis (RRMS) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Relapsing-Remitting Multiple Sclerosis (RRMS) .

Treatment

It covers the details of conventional and current medical therapies available in the Relapsing-Remitting Multiple Sclerosis (RRMS) market for the treatment of the condition. It also provides Relapsing-Remitting Multiple Sclerosis (RRMS) treatment algorithms and guidelines in the United States, Europe, and Japan.

Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology

The Relapsing-Remitting Multiple Sclerosis (RRMS) epidemiology division provide insights about historical and current Relapsing-Remitting Multiple Sclerosis (RRMS) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Relapsing-Remitting Multiple Sclerosis (RRMS) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology

The epidemiology segment also provides the Relapsing-Remitting Multiple Sclerosis (RRMS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Relapsing-Remitting Multiple Sclerosis (RRMS) Drug Chapters

Drug chapter segment of the Relapsing-Remitting Multiple Sclerosis (RRMS) report encloses the detailed analysis of Relapsing-Remitting Multiple Sclerosis (RRMS) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Relapsing-Remitting Multiple Sclerosis (RRMS) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Relapsing-Remitting Multiple Sclerosis (RRMS) treatment.

Relapsing-Remitting Multiple Sclerosis (RRMS) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Relapsing-Remitting Multiple Sclerosis (RRMS) treatment.

Relapsing-Remitting Multiple Sclerosis (RRMS) Market Outlook

The Relapsing-Remitting Multiple Sclerosis (RRMS) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Relapsing-Remitting Multiple Sclerosis (RRMS) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Relapsing-Remitting Multiple Sclerosis (RRMS) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Relapsing-Remitting Multiple Sclerosis (RRMS) market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Relapsing-Remitting Multiple Sclerosis (RRMS) market in 7MM.

The United States Market Outlook

This section provides the total Relapsing-Remitting Multiple Sclerosis (RRMS) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Relapsing-Remitting Multiple Sclerosis (RRMS) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Relapsing-Remitting Multiple Sclerosis (RRMS) market size and market size by therapies in Japan is also mentioned.

Relapsing-Remitting Multiple Sclerosis (RRMS) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Relapsing-Remitting Multiple Sclerosis (RRMS) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Relapsing-Remitting Multiple Sclerosis (RRMS) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Relapsing-Remitting Multiple Sclerosis (RRMS) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Relapsing-Remitting Multiple Sclerosis (RRMS) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Relapsing-Remitting Multiple Sclerosis (RRMS) emerging therapies.

Reimbursement Scenario in Relapsing-Remitting Multiple Sclerosis (RRMS)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Relapsing-Remitting Multiple Sclerosis (RRMS) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Relapsing-Remitting Multiple Sclerosis (RRMS) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Relapsing-Remitting Multiple Sclerosis (RRMS) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Relapsing-Remitting Multiple Sclerosis (RRMS) , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Relapsing-Remitting Multiple Sclerosis (RRMS) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Relapsing-Remitting Multiple Sclerosis (RRMS) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Relapsing-Remitting Multiple Sclerosis (RRMS) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Relapsing-Remitting Multiple Sclerosis (RRMS) market

Report Highlights:

  • In the coming years, Relapsing-Remitting Multiple Sclerosis (RRMS) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Relapsing-Remitting Multiple Sclerosis (RRMS) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Relapsing-Remitting Multiple Sclerosis (RRMS) . Launch of emerging therapies will significantly impact the Relapsing-Remitting Multiple Sclerosis (RRMS) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Relapsing-Remitting Multiple Sclerosis (RRMS)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Relapsing-Remitting Multiple Sclerosis (RRMS) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Relapsing-Remitting Multiple Sclerosis (RRMS) Pipeline Analysis
  • Relapsing-Remitting Multiple Sclerosis (RRMS) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Relapsing-Remitting Multiple Sclerosis (RRMS) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Relapsing-Remitting Multiple Sclerosis (RRMS) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the Relapsing-Remitting Multiple Sclerosis (RRMS) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Relapsing-Remitting Multiple Sclerosis (RRMS) total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Relapsing-Remitting Multiple Sclerosis (RRMS) market size during the forecast period (2017-2030)?
  • At what CAGR, the Relapsing-Remitting Multiple Sclerosis (RRMS) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Relapsing-Remitting Multiple Sclerosis (RRMS) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Relapsing-Remitting Multiple Sclerosis (RRMS) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Relapsing-Remitting Multiple Sclerosis (RRMS) ?
  • What is the historical Relapsing-Remitting Multiple Sclerosis (RRMS) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Relapsing-Remitting Multiple Sclerosis (RRMS) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Relapsing-Remitting Multiple Sclerosis (RRMS) ?
  • Out of all 7MM countries, which country would have the highest prevalent population of Relapsing-Remitting Multiple Sclerosis (RRMS) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Relapsing-Remitting Multiple Sclerosis (RRMS) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) in the USA, Europe, and Japan?
  • What are the Relapsing-Remitting Multiple Sclerosis (RRMS) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) ?
  • How many therapies are developed by each company for Relapsing-Remitting Multiple Sclerosis (RRMS) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Relapsing-Remitting Multiple Sclerosis (RRMS) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Relapsing-Remitting Multiple Sclerosis (RRMS) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Relapsing-Remitting Multiple Sclerosis (RRMS) and their status?
  • What are the key designations that have been granted for the emerging therapies for Relapsing-Remitting Multiple Sclerosis (RRMS) ?
  • What are the global historical and forecasted market of Relapsing-Remitting Multiple Sclerosis (RRMS) ?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Relapsing-Remitting Multiple Sclerosis (RRMS) market
  • To understand the future market competition in the Relapsing-Remitting Multiple Sclerosis (RRMS) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Relapsing-Remitting Multiple Sclerosis (RRMS) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Relapsing-Remitting Multiple Sclerosis (RRMS) market
  • To understand the future market competition in the Relapsing-Remitting Multiple Sclerosis (RRMS) market

Table of Contents

1. Key Insights

2. Executive Summary of Relapsing-Remitting Multiple Sclerosis (RRMS)

3. Competitive Intelligence Analysis for Relapsing-Remitting Multiple Sclerosis (RRMS)

4. Relapsing-Remitting Multiple Sclerosis (RRMS) : Market Overview at a Glance

  • 4.1. Relapsing-Remitting Multiple Sclerosis (RRMS) Total Market Share (%) Distribution in 2017
  • 4.2. Relapsing-Remitting Multiple Sclerosis (RRMS) Total Market Share (%) Distribution in 2030

5. Relapsing-Remitting Multiple Sclerosis (RRMS) : Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Relapsing-Remitting Multiple Sclerosis (RRMS) Treatment and Management
  • 8.2. Relapsing-Remitting Multiple Sclerosis (RRMS) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Relapsing-Remitting Multiple Sclerosis (RRMS) Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Relapsing-Remitting Multiple Sclerosis (RRMS) : Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Relapsing-Remitting Multiple Sclerosis (RRMS) Market Size in 7MM
  • 13.3. Relapsing-Remitting Multiple Sclerosis (RRMS) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Relapsing-Remitting Multiple Sclerosis (RRMS) Total Market Size in the United States
    • 15.1.2. Relapsing-Remitting Multiple Sclerosis (RRMS) Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Relapsing-Remitting Multiple Sclerosis (RRMS) Total Market Size in Germany
    • 15.3.2. Relapsing-Remitting Multiple Sclerosis (RRMS) Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Relapsing-Remitting Multiple Sclerosis (RRMS) Total Market Size in France
    • 15.4.2. Relapsing-Remitting Multiple Sclerosis (RRMS) Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Relapsing-Remitting Multiple Sclerosis (RRMS) Total Market Size in Italy
    • 15.5.2. Relapsing-Remitting Multiple Sclerosis (RRMS) Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Relapsing-Remitting Multiple Sclerosis (RRMS) Total Market Size in Spain
    • 15.6.2. Relapsing-Remitting Multiple Sclerosis (RRMS) Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Relapsing-Remitting Multiple Sclerosis (RRMS) Total Market Size in the United Kingdom
    • 15.7.2. Relapsing-Remitting Multiple Sclerosis (RRMS) Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Relapsing-Remitting Multiple Sclerosis (RRMS) Total Market Size in Japan
    • 15.8.3. Relapsing-Remitting Multiple Sclerosis (RRMS) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Relapsing-Remitting Multiple Sclerosis (RRMS)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.

List of Tables

  • Table 1: 7MM Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology (2017-2030)
  • Table 2: 7MM Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases (2017-2030)
  • Table 3: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in the United States (2017-2030)
  • Table 4: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in Germany (2017-2030)
  • Table 6: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in France (2017-2030)
  • Table 8: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in Italy (2017-2030)
  • Table 10: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in Spain (2017-2030)
  • Table 12: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in the UK (2017-2030)
  • Table 14: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in Japan (2017-2030)
  • Table 16: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17: Drug Name, Clinical Trials by Recruitment status
  • Table 18: Drug Name, Clinical Trials by Zone
  • Table 19: Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20: Region-wise Market Size in USD, Million (2017-2030)
  • Table 21: 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22: United States Market Size in USD, Million (2017-2030)
  • Table 23: United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24: Germany Market Size in USD, Million (2017-2030)
  • Table 25: Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26: France Market Size in USD, Million (2017-2030)
  • Table 27: France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28: Italy Market Size in USD, Million (2017-2030)
  • Table 29: Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30: Spain Market Size in USD, Million (2017-2030)
  • Table 31: Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32: United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33: United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34: Japan Market Size in USD, Million (2017-2030)
  • Table 35: Japan Market Size by Therapy in USD, Million (2017-2030)

The list of tables is not exhaustive; the final content may vary

List of Figures

  • Figure 1: 7MM Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology (2017-2030)
  • Figure 2: 7MM Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases (2017-2030)
  • Figure 3: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in the United States (2017-2030)
  • Figure 4: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in Germany (2017-2030)
  • Figure 6: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in France (2017-2030)
  • Figure 8: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in Italy (2017-2030)
  • Figure 10: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in Spain (2017-2030)
  • Figure 12: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in the UK (2017-2030)
  • Figure 14: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15: Relapsing-Remitting Multiple Sclerosis (RRMS) Epidemiology in Japan (2017-2030)
  • Figure 16: Relapsing-Remitting Multiple Sclerosis (RRMS) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17: Drug Name, Clinical Trials by Recruitment status
  • Figure 18: Drug Name, Clinical Trials by Zone
  • Figure 19: Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20: Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21: 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22: United States Market Size in USD, Million (2017-2030)
  • Figure 23: United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24: Germany Market Size in USD, Million (2017-2030)
  • Figure 25: Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26: France Market Size in USD, Million (2017-2030)
  • Figure 27: France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28: Italy Market Size in USD, Million (2017-2030)
  • Figure 29: Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30: Spain Market Size in USD, Million (2017-2030)
  • Figure 31: Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32: United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33: United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34: Japan Market Size in USD, Million (2017-2030)
  • Figure 35: Japan Market Size by Therapy in USD, Million (2017-2030)

The list of figures is not exhaustive; the final content may vary.